Doctors diagnosed Christopher Gregg, PhD, member of the Nuclear Control of Cell Growth and Differentiation Program at Huntsman Cancer Institute at the University of Utah and neuroscientist and professor of neurobiology and human genetics at the U, with stage 4 metastatic breast cancer in 2018.
Artificial intelligence can track metastatic cancer symptoms and predict drug resistance, which encourages doctors to begin effective Extinction therapy.
Doctors diagnosed Christopher Gregg, Ph.D., member of the Nuclear Control of Cell Growth and Differentiation Program at Huntsman Cancer Institute at the University of Utah (the U) and neuroscientist and professor of neurobiology and human genetics at the U, with stage 4 metastatic breast cancer in 2018.